^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-13 inhibitor

    Associations

    News

    Trials
    1d
    A Study Evaluating APG777 in Atopic Dermatitis (clinicaltrials.gov)
    P2, N=470, Active, not recruiting, Apogee Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    7d
    A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, UCB Biopharma SRL
    New P2 trial
    13d
    Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Generate Biomedicines | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026
    Enrollment closed • Trial completion date • First-in-human
    29d
    A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Zai Lab (Shanghai) Co., Ltd.
    New P1 trial
    1m
    A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. (clinicaltrials.gov)
    P2, N=246, Recruiting, Keymed Biosciences Co.Ltd
    New P2 trial
    2ms
    A Phase 1, First in Human, Randomised, Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Investigate the Safety, Tolerability and Pharmacokinetics of GB-7624 administered subcutaneously in Healthy Adult participants (ACTRN12625000229471)
    P1, N=40, Active, not recruiting, Generate Biomedicines Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis (clinicaltrials.gov)
    P3, N=48, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    2ms
    A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (clinicaltrials.gov)
    P1/2, N=273, Completed, UCB Biopharma SRL | Active, not recruiting --> Completed
    Trial completion
    2ms
    PERSEPHONE: Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype (clinicaltrials.gov)
    P3, N=942, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    THESEUS: Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype (clinicaltrials.gov)
    P3, N=942, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Apr 2026 | Trial primary completion date: Jun 2026 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    3ms
    AIRPHRODITE: Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma. (clinicaltrials.gov)
    P2, N=900, Recruiting, Sanofi | N=530 --> 900
    Enrollment change